689,833 Shares in AxoGen, Inc. $AXGN Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 689,833 shares of the medical equipment provider's stock, valued at approximately $31,863,000. TimesSquare Capital Management LLC owned about 1.28% of AxoGen at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. MCF Advisors LLC acquired a new position in shares of AxoGen during the fourth quarter worth about $30,000. Arax Advisory Partners lifted its position in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 819 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in AxoGen in the fourth quarter valued at about $36,000. Kestra Advisory Services LLC purchased a new stake in AxoGen in the 4th quarter valued at approximately $39,000. Finally, KBC Group NV purchased a new stake in AxoGen in the 1st quarter valued at approximately $41,000. 80.29% of the stock is owned by institutional investors and hedge funds.

AxoGen Stock Performance

Shares of AXGN stock opened at $49.15 on Tuesday. The stock has a fifty day moving average price of $43.58 and a 200 day moving average price of $38.58. The stock has a market cap of $2.64 billion, a PE ratio of -72.28 and a beta of 1.11. AxoGen, Inc. has a 1 year low of $13.64 and a 1 year high of $49.93. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The company had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. Sell-side analysts forecast that AxoGen, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell sold 13,353 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $48.42, for a total value of $646,552.26. Following the sale, the director directly owned 107,976 shares of the company's stock, valued at approximately $5,228,197.92. This represents a 11.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the sale, the executive vice president directly owned 50,135 shares in the company, valued at approximately $2,373,390.90. The trade was a 57.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 95,003 shares of company stock worth $4,482,997 in the last three months. Corporate insiders own 2.44% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on AXGN shares. Citigroup reissued a "market outperform" rating on shares of AxoGen in a research note on Thursday, July 30th. Lake Street Capital lifted their price target on AxoGen from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, April 23rd. Raymond James Financial reaffirmed an "outperform" rating and set a $48.00 price objective on shares of AxoGen in a report on Wednesday, April 29th. Wells Fargo & Company increased their price objective on AxoGen from $40.00 to $48.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 29th. Finally, HC Wainwright raised their target price on AxoGen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AxoGen presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source